Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01299285

Enrollment

Registered

2011-02-18

Start date

2011-02-28

Completion date

2011-03-31

Last updated

2017-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

Absorption, Distribution, Metabolism, Excretion, Mass balance, Metabolic profile, Radiolabeled study, 14C

Brief summary

This is a single dose study of radiolabeled \[14C\]-LY3009104 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY3009104. This study requires minimum of 7 days and maximum of 22 days stay. This study is for research purposes only and is not intended to treat any medical condition.

Interventions

DRUGLY3009104

Administered orally

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Overtly healthy males, as determined by medical history and physical examination * Will either be sterile or, if sexually active, agree to use a reliable method of birth control from check-in until 3 months after the end of the study * Body mass index (BMI) between 19 and 30 kilogram/square meter (kg/m²) * Experience on average 1 to 2 bowel movements per day * Clinical laboratory test results within the normal reference range for the clinical research unit (CRU) or, results with acceptable deviations which are judged to be not clinically significant by the investigator * Normal blood pressure and heart rate (sitting) as determined by the investigator * Venous access sufficient to allow blood sampling * Are reliable and willing to make themselves available for the duration of the study, and are willing to abide by the CRU policies and procedures, and study restrictions * Have given written informed consent approved by Lilly and the Institutional Review Board (IRB) governing the CRU

Exclusion criteria

* Are currently enrolled in, have completed or discontinued, a clinical trial involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically, or medically compatible with this study * Have known allergies to LY3009104, related compounds, or any components of the formulation * Have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY3009104 * History or presence of an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, is clinically significant * Current or recent history (\<30 days prior to Screening and/or \<45 days prior to Check-in) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection * An Absolute Neutrophil Count (ANC) less than 2000 cells/microliter. For abnormal values a single repeat will be allowed * Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data * Show evidence of significant active neuropsychiatric disease and in particular evidence of significant medical or psychiatric illness within the past 12 months * Have known substance dependence or abuse within 6 months prior to the study (according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition \[DSM-IV\] diagnosis), or regularly use known drugs of abuse and/or show positive findings on urinary drug screening * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies * Show evidence of hepatitis C and/or positive hepatitis C antibody * Evidence hepatitis B (active or surface antigen positive \[HBsAg+\]) or hepatitis B core antibody positive, hepatitis B surface antibody negative (HBcAb+, HBsAb-) * Use of prescription medication; over-the-counter medication; or herbal preparations containing St. John's Wort, kava, garlic, ginger, gingko biloba, or guarana within 14 days prior to admission * Consumption of grapefruit or grapefruit-containing foods or juices within 7 days prior to dosing or at any time during the study * Have an average weekly alcohol intake that exceeds 15 units per week, or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 oz or 360 milliliter (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) * Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine restrictions (no caffeine 48 hours prior to admission until the end of study * Use of tobacco or nicotine-replacement products within the 6 months prior to study entry or at any time during the study * Have donated blood of more than 500 mL within the last month * Have participated in a 14C-study within the last 6 months prior to Check-in for this study. The total exposure from this study and the previous study must be within the Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR 361.1), for example less than 5,000 millirem (mrem)/year whole body annual exposure * Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)

Design outcomes

Primary

Measure	Time frame
Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces	Baseline up to 120 hours

Secondary

Measure	Time frame	Description
Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]	Baseline up to 48 hours	—
Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax)	Baseline up to 48 hours	—
Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax)	Baseline up to 48 hours	—
Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)]	Baseline up to 48 hours	—
Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine	Baseline up to 48 hours	Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported. Only those metabolites that were detectable in the urine are included in the report.
Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces	Baseline up to 72 hours	Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported. Only those metabolites that were detectable in the feces are included in the report.
Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma	Baseline up to 24 hours	—
Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax)	Baseline up to 48 hours	—

Countries

United States

Participant flow

Participants by arm

Arm	Count
LY3009104 Single 10-mg oral dose containing 100 microcuries of 14C-labeled LY3009104	6
Total	6

Baseline characteristics

Characteristic	LY3009104
Age, Continuous	36.7 years STANDARD_DEVIATION 11.3
Race/Ethnicity, Customized Asian	1 participants
Race/Ethnicity, Customized White	5 participants
Region of Enrollment United States	6 participants
Sex: Female, Male Female	0 Participants
Sex: Female, Male Male	6 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	1 / 6
serious Total, serious adverse events	0 / 6